| When Novo Nordisk (NVO) launched its Type 2 diabetes treatment, Ozempic (semaglutide), in 2017, it unknowingly triggered a new kind of "gold rush." The once-weekly injection turned out to be remarkably effective in helping patients lose weight. Novo Nordisk got wise: It quickly spun semaglutide into a weight-loss-approved version, Wegovy. Folks caught on. Demand soared. Within just five years of these revolutionary drugs being on the market, Novo Nordisk's market value quadrupled – turning it into the single most valuable European company by market cap. But even that's nothing compared to what we're seeing now. In the first nine months of 2023, Wegovy sales rocketed more than 480%. Eli Lilly's (LLY) version of the Type 2 diabetes "miracle" drug, Mounjaro (tirzepatide), racked up $1.41 billion in the third quarter alone. And the profits should only ramp up from here. Eli Lilly gained FDA approval on Zepbound (tirzepatide), the weight-loss-approved version of Mounjaro, earlier this month. Patients are already clamoring to get their hands on it. 
And pill versions of these weight-loss drugs are on the way from both NVO and LLY to make these medications more accessible than ever. Getting in Early on the Weight-Loss "Mega" Trend Industry watchers believe this could be the most lucrative drug class to ever hit the market. Projections put semaglutide's eventual annual value as high as $300 billion. And again, that's just for Novo Nordisk's semaglutide. It makes sense: Obesity is a big problem, affecting 42% of adults in America, according to the National Institutes of Health (NIH). A "magic pill" is a whole lot more alluring than diet and exercise. And influential celebrities from NBA great Charles Barkley to Tesla (TSLA) CEO Elon Musk touting their success stories have only added fuel to the fire. 
With a direct line to what's hot on Main Street, we've been keeping close tabs on this weight-loss "mega" trend here at LikeFolio. We could see consumers talking about taking these weight-loss drugs at unprecedented levels... 
That early lead allowed our followers to bank 174% on WW International (WW) earlier this year. The company (formerly known as WeightWatchers) acquired telehealth provider Sequence, giving it the ability to connect its users via medical doctors to those trendy weight-loss drugs. It was enough to send WW shares flying more than 50% in a single day. 
And we can show you the next big weight-loss winner today... Spotting the Next Big Weight-Loss Winner With this opportunity, we're not chasing after those half-a-trillion-dollar pharmaceutical giants. We're tapping into our LikeFolio edge – identifying the under-the-radar player gaining momentum on Main Street and placing our trade well before the Wall Street pros. LikeFolio data points to a 68% year-over-year increase in consumer demand for this tiny telehealth company that's set to enter the lucrative weight-loss race by year-end. Most investors haven't even caught on to that fact, which is why shares are still trading under $10. But once January rolls around, and its weight-loss business launches, this name will be on every investor's lips. You'll want to at least be armed with the details before that happens. Landon and I will give you the inside scoop on our biggest prediction of 2024 right here. Click here to access now Until next time, | 
没有评论:
发表评论